

Regulatory Announcement

[Go to market news section](#)



Company	Fulcrum Pharma PLC
TIDM	FUL
Headline	Completion of Earn Out
Released	07:00 21-Feb-07
Number	5897R

RNS Number:5897R
 Fulcrum Pharma PLC
 20 February 2007

FULCRUM PHARMA PLC
 ("the Group" or "the Company")

Successful Completion of Quadramed Earn Out

Further Expansion of Edinburgh Office

Fulcrum Pharma plc (AIM:FUL), the drug development and strategic outsourcing services company, is pleased to announce the results of the earnout relating to the acquisition of Quadramed Limited ("Quadramed").

Quadramed was acquired at the beginning of February 2006 and was the first step in the delivery of Fulcrum's strategic objective to significantly expand its capability in pharmaceutical regulatory services.

As reported in the company's Annual Report for 2006, Quadramed was an important contributor to Fulcrum's performance and sales growth. During the earnout period Quadramed's trading has been better than anticipated, with its fee income in earnout period expected to show a 50% increase over the corresponding twelve months in the previous year.

As a result of Quadramed's strong performance, the maximum deferred consideration of £500,000 is payable in convertible loan notes which are to be issued as at 28th February 2007. The convertible loan notes are repayable as to £250,000 on 31st August 2007 and to £250,000 on 28th February 2008. Interest is payable on the loan notes at 2% over bank base rate and the terms of conversion are that the holders of the notes shall be entitled to convert the notes into ordinary shares in the capital of the Company on the basis of one new ordinary share per 6 pence of loan note principal.

As part of the Company's planned organic growth, Quadramed has also taken further premises alongside Fulcrum's existing Edinburgh office to expand its services, in particular in regulatory compliance. These premises have been integrated to share common services. Quadramed has received grant assistance of up to £130,000 from the Scottish Executive as part of its expansion.

The enlarged Edinburgh office, located at the Heriot-Watt University Research Park, will further complement Fulcrum's other European offices in Hemel Hempstead, Midhurst and Strasbourg and will allow the Group to continue the growth of its drug development and regulatory resources .

Jon Court, Chief Executive of Fulcrum Pharma said: "I am very pleased with the success of the Quadramed acquisition. The further expansion of the Edinburgh office will enable our business to increase both the range of its services and the volume of work for our international client base."

FOR FURTHER INFORMATION, PLEASE CONTACT:

Fulcrum Pharma Plc
Jon Court, Chief Executive 0870 7107152

About Fulcrum Pharma plc

Fulcrum Pharma plc is a drug development and regulatory services business that provides global expertise to achieve drug development and regulatory approval milestones.

Fulcrum Pharma offers immediate access to a highly credible, integrated development team that provides strategic and operational leadership required to ensure that new drugs move smoothly from discovery research to product approval

Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange having successfully floated in March 2000.

This information is provided by RNS
The company news service from the London Stock Exchange

END

Close

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

